Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
FAQ
- What is Vir Biotechnology, Inc.'s D&A?
- Vir Biotechnology, Inc. (VIR) reported D&A of $2.8M in Q2 2026.
- How has Vir Biotechnology, Inc.'s D&A changed year-over-year?
- Vir Biotechnology, Inc.'s D&A decreased by 3.9% year-over-year, from $2.92M to $2.8M.
- What is the long-term trend for Vir Biotechnology, Inc.'s D&A?
- Over 4 years (2021 to 2025), Vir Biotechnology, Inc.'s D&A has grown at a 21.5% compound annual growth rate (CAGR), from $5.36M to $11.68M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Vir Biotechnology, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude